Randomized phase III study with irinotecan + best supportive care versus only best supportive care as second line therapy for metastatic gastric cancer
Latest Information Update: 11 Aug 2011
Price :
$35 *
At a glance
- Drugs Irinotecan (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 08 Jul 2011 Results published in the European Journal of Cancer.
- 12 Oct 2009 Primary endpoint 'Overall survival' has been met.
- 12 Oct 2009 Results have been reported at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.